CML is a relatively rare form of blood cancer which occurs when the bone marrow produces too many white blood cells (myeloid cells) that are not fully developed and function poorly.1 The overproduction of these cells prevents the bone marrow from producing enough healthy blood cells.

Advances in treatment have helped to transform CML from a life-threatening disease to, in most cases, a chronic condition, and in the last decade mortality rates have decreased by a fifth in the UK.2 CML is now commonly treated with TKIs, which help stop the production of the abnormal white blood cells.3 Around 85–95% of people treated with TKIs will live for at least 5 years after CML is diagnosed.1 Other therapies for CML include chemotherapy and, in some cases, stem cell or bone marrow transplants.3

One of the new emerging goals of CML management for some patients is TFR. For those patients who respond very well to treatment, their leukaemic burden is reduced to a level at which they may be able to stop treatment. In order to be considered for attempting TFR, a patient must have demonstrated a sustained deep molecular response prior to stopping TKI therapy. Discontinuation for TFR requires strict eligibility criteria and increased frequency of monitoring.4–6 The decision to stop TKI therapy should only be attempted in consultation with the patient’s clinician and under strict, frequent monitoring in a clinical setting. Treatment should be reinitiated within 4 weeks if a patient loses their response while in TFR.4,5


CML, chronic myeloid leukaemia; TFR, treatment-free remission; TKI, tyrosine kinase inhibitor.


  1. NHS Choices. Chronic myeloid leukaemia: Overview. Available at: Last accessed May 2020.

  2. Cancer Research UK. Chronic myeloid leukaemia (CML) statistics. Available at: Last accessed May 2020.

  3. NHS Choices. Treatments for chronic myeloid leukaemia. Available at: Last accessed May 2020.

  4. Tasigna® (nilotinib 200 mg and 50 mg) Summary of Product Characteristics. 2019.

  5. Tasigna® (nilotinib 150 mg) Summary of Product Characteristics. 2019.

  6. Hochhaus A, et al. Ann Oncol. 2017;28(suppl 4):iv41–iv51.

Rate this content: 
No votes yet
HCP20-C029 June 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]